Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study

INTRODUCTION: The glucagon-like peptide-1 agonist (GLP1-RA) liraglutide is currently approved for the treatment of both obesity and type 2 diabetes (T2DM). We investigated whether the effect of this agent on cardiometabolic parameters in subjects with T2DM varied in relation to the concomitant prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Nikolic, Dragana, Patti, Angelo M., Giglio, Rosaria V., Chianetta, Roberta, Castellino, Giuseppa, Magán-Fernández, Antonio, Citarrella, Roberto, Papanas, Nikolaos, Janez, Andrej, Stoian, Anca Pantea, Rizvi, Ali A., Rizzo, Manfredi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853434/
https://www.ncbi.nlm.nih.gov/pubmed/35167051
http://dx.doi.org/10.1007/s13300-022-01217-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853434/
https://www.ncbi.nlm.nih.gov/pubmed/35167051
http://dx.doi.org/10.1007/s13300-022-01217-z

Ejemplares similares